In vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat

Neuropharmacology

Volumn 64, Issue , 2013, Pages 224-239

  Gilmour, Gary ^a   Broad, Lisa M ^a   Wafford, Keith A ^a   Britton, Thomas ^a   Colvin, Ellen M ^a   Fivush, Adam ^a   Gastambide, Francois ^a   Getman, Brian ^a   Heinz, Beverly A ^a   McCarthy, Andrew P ^a   Prieto, Lourdes ^a   Shanks, Elaine ^a   Smith, Janice W ^a   Taboada, Lorena ^a   Edgar, Dale M ^a   Tricklebank, Mark D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Glutamate; mGlu5 receptor; NMDA receptor antagonist; Psychosis; Schizophrenia

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 3 TERT BUTYL 7 [3 (4 FLUOROPHENYL) 1,2,4 OXADIAZOL 5 YL] 5,6,7,8 TETRAHYDRO[1,2,4]TRIAZOLO[4,3 A]PYRIDINE; 4 FLUOROPHENYL [3 [3 (4 FLUOROPHENYL)[1,2,4]OXADIAZOL 5 YL]PIPERIDIN 1 YL]METHANONE; ADX 47273; HALOPERIDOL; LSN 2463359; LSN 2814617; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N (1 METHYLETHYL) 5 (PYRIDIN 4 YLETHYNYL)PYRIDINE 2 CARBOXAMIDE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AROUSAL; ARTICLE; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ELECTROENCEPHALOGRAM; FEMALE; FETUS; HIPPOCAMPUS; HYPERACTIVITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SLEEP; STIMULUS RESPONSE; WAKEFULNESS;

ALLOSTERIC REGULATION; ANIMALS; AROUSAL; BEHAVIOR, ANIMAL; CELL LINE; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; EMBRYO, MAMMALIAN; EXCITATORY AMINO ACID AGONISTS; HUMANS; MALE; NEURONS; NOOTROPIC AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RECOMBINANT PROTEINS; SCHIZOPHRENIA; SLEEP STAGES; TISSUE DISTRIBUTION;

EID: 84866375222     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.07.030     Document Type: Article

References (62)

1. F. Ango, D. Robbe, J.C. Tu, B. Xiao, P.F. Worley, J.P. Pin, J. Bockaert, and L. Fagni Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons Mol. Cell. Neurosci. 20 2002 323 329
2. S. Attucci, V. Carla, G. Mannaioni, and F. Moroni Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges Br. J. Pharmacol. 132 2001 799 806
3. B.D. Auerbach, E.K. Osterweil, and M.F. Bear Mutations causing syndromic autism define an axis of synaptic pathophysiology Nature 480 2011 63 68
4. H. Awad, G.W. Hubert, Y. Smith, A.I. Levey, and P.J. Conn Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus J. Neurosci. 20 2000 7871 7879
5. J.E. Ayala, Y. Chen, J.L. Banko, D.J. Sheffler, R. Williams, A.N. Telk, N.L. Watson, Z. Xiang, Y. Zhang, P.J. Jones, C.W. Lindsley, M.F. Olive, and P.J. Conn mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning Neuropsychopharmacology 34 2009 2057 2071
6. T.M. Ballard, M.L. Woolley, E. Prinssen, J. Huwyler, R. Porter, and W. Spooren The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison Psychopharmacology (Berl.) 179 2005 218 229
7. M.K. Bird, and A.J. Lawrence The promiscuous mGlu5 receptor - a range of partners for therapeutic possibilities? Trends Pharmacol. Sci. 30 2009 617 623
8. 2+ signaling initiated by the type 5 metabotropic glutamate receptor Mol. Pharmacol. 76 2009 1302 1313
9. U.C. Campbell, K. Lalwani, L. Hernandez, G.G. Kinney, P.J. Conn, and L.J. Bristow The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats Psychopharmacology (Berl.) 175 2004 310 318
10. Y. Chen, C. Goudet, J.P. Pin, and P.J. Conn N-{4-Chloro-2-[(1,3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors Mol. Pharmacol. 73 2008 909 918
11. Y. Chen, Y. Nong, C. Goudet, K. Hemstapat, P.T. de, J.P. Pin, and P.J. Conn Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses Mol. Pharmacol. 71 2007 1389 1398
12. E. Chernet, L.J. Martin, D. Li, A.B. Need, V.N. Barth, K.S. Rash, and L.A. Phebus Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples Life Sci. 78 2005 340 346
13. Y. Chudasama, and J.L. Muir A behavioural analysis of the delayed non-matching to position task: the effects of scopolamine, lesions of the fornix and of the prelimbic region on mediating behaviours by rats Psychopharmacology (Berl.) 134 1997 73 82
14. R.M. Cleva, and M.F. Olive Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders Molecules 16 2011 2097 2106
15. P.J. Conn, C.W. Lindsley, and C.K. Jones Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30 2009 25 31
16. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237
17. J.M. Darrah, M.R. Stefani, and B. Moghaddam Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm Behav. Pharmacol. 19 2008 225 234
18. M.B. Dash, C.L. Douglas, V.V. Vyazovskiy, C. Cirelli, and G. Tononi Long-term homeostasis of extracellular glutamate in the rat cerebral cortex across sleep and waking states J. Neurosci. 29 2009 620 629
19. A.J. Doherty, M.J. Palmer, J.M. Henley, G.L. Collingridge, and D.E. Jane (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus Neuropharmacology 36 1997 265 267
20. S.B. Dunnett Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats Psychopharmacology (Berl.) 87 1985 357 363
21. D.M. Edgar, and W.F. Seidel Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat J. Pharmacol. Exp. Ther. 283 1997 757 769
22. A.C. Emery, S. Pshenichkin, G.R. Takoudjou, E. Grajkowska, B.B. Wolfe, and J.T. Wroblewski The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, beta-arrestin-1-dependent ERK phosphorylation J. Biol. Chem. 285 2010 26041 26048
23. F. Gasparini, K. Lingenhohl, N. Stoehr, P.J. Flor, M. Heinrich, I. Vranesic, M. Biollaz, H. Allgeier, R. Heckendorn, S. Urwyler, M.A. Varney, E.C. Johnson, S.D. Hess, S.P. Rao, A.I. Sacaan, E.M. Santori, G. Velicelebi, and R. Kuhn 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38 1999 1493 1503
24. F. Gastambide, M.C. Cotel, G. Gilmour, M.J. O'Neill, T.W. Robbins, and M.D. Tricklebank Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator Neuropsychopharmacology 37 2012 1057 1066
25. Gastambide, F.; Gilmour, G.; Robbins, T.W.; Tricklebank, M.D. The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology, in this issue.
26. G. Gilmour, S. Dix, L. Fellini, F. Gastambide, N. Plath, T. Steckler, J. Talpos, and M. Tricklebank NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis Neuropharmacology 62 2012 1401 1412
27. A.S. Hammond, A.L. Rodriguez, S.D. Townsend, C.M. Niswender, K.J. Gregory, C.W. Lindsley, and P.J. Conn Discovery of a novel chemical class of mGlu(5) allosteric ligands with distinct modes of pharmacology ACS Chem. Neurosci. 1 2010 702 716
28. S. Hasan, S. Pradervand, A. Ahnaou, W. Drinkenburg, M. Tafti, and P. Franken How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion Neuropsychopharmacology 34 2009 1625 1640
29. S.A. Hays, K.M. Huber, and J.R. Gibson Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry J. Neurosci. 31 2011 14223 14234
30. H. Homayoun, M.R. Stefani, B.W. Adams, G.D. Tamagan, and B. Moghaddam Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release Neuropsychopharmacology 29 2004 1259 1269
31. G.G. Kinney, M. Burno, U.C. Campbell, L.M. Hernandez, D. Rodriguez, L.J. Bristow, and P.J. Conn Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents J. Pharmacol. Exp. Ther. 306 2003 116 123
32. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 313 2005 199 206
33. J.W. Kinney, C.N. Davis, I. Tabarean, B. Conti, T. Bartfai, and M.M. Behrens A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons J. Neurosci. 26 2006 1604 1615
34. E. Koros, H. Rosenbrock, G. Birk, C. Weiss, and F. Sams-Dodd The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats Neuropsychopharmacology 32 2007 562 576
35. V. Kumar, P.G. Fahey, Y.J. Jong, N. Ramanan, and K.L. O'Malley Activation of intracellular metabotropic glutamate receptor 5 in striatal neurons leads to up-regulation of genes associated with sustained synaptic transmission including Arc/Arg3.1 protein J. Biol. Chem. 287 2012 5412 5425
36. L. Lecourtier, H. Homayoun, G. Tamagnan, and B. Moghaddam Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex Biol. Psychiatry 62 2007 739 746
37. F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P.J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, D. Smith, M. Olsen, E. Kouranova, M. Lai, F. Pruthi, C. Pulicicchio, M. Day, A. Gilbert, M.H. Pausch, N.J. Brandon, C.E. Beyer, T.A. Comery, S. Logue, S. Rosenzweig-Lipson, and K.L. Marquis ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol- 5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther. 327 2008 827 839
38. G. Mannaioni, M.J. Marino, O. Valenti, S.F. Traynelis, and P.J. Conn Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function J. Neurosci. 21 2001 5925 5934
39. S. Maret, S. Dorsaz, L. Gurcel, S. Pradervand, B. Petit, C. Pfister, O. Hagenbuchle, B.F. O'Hara, P. Franken, and M. Tafti Homer1a is a core brain molecular correlate of sleep loss Proc. Natl. Acad. Sci. U. S. A. 104 2007 20090 20095
40. L.T. May, V.A. Avlani, P.M. Sexton, and A. Christopoulos Allosteric modulation of G protein-coupled receptors Curr. Pharm. Des. 10 2004 2003 2013
41. N. Naidoo, M. Ferber, R.J. Galante, B. McShane, J.H. Hu, J. Zimmerman, G. Maislin, J. Cater, A. Wyner, P. Worley, and A.I. Pack Role of homer proteins in the maintenance of sleep-wake States PLoS One 7 2012 e35174
42. M.J. Noetzel, J.M. Rook, P.N. Vinson, H.P. Cho, E. Days, Y. Zhou, A.L. Rodriguez, H. Lavreysen, S.R. Stauffer, C.M. Niswender, Z. Xiang, J.S. Daniels, C.K. Jones, C.W. Lindsley, C.W. Weaver, and P.J. Conn Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function Mol. Pharmacol. 81 2012 120 133
43. J.A. O'Brien, W. Lemaire, T.B. Chen, R.S. Chang, M.A. Jacobson, S.N. Ha, C.W. Lindsley, H.J. Schaffhauser, C. Sur, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol. Pharmacol. 64 2003 731 740
44. J.A. O'Brien, W. Lemaire, M. Wittmann, M.A. Jacobson, S.N. Ha, D.D. Wisnoski, C.W. Lindsley, H.J. Schaffhauser, B. Rowe, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain J. Pharmacol. Exp. Ther. 309 2004 568 577
45. A. Pagano, D. Ruegg, S. Litschig, N. Stoehr, C. Stierlin, M. Heinrich, P. Floersheim, L. Prezeau, F. Carroll, J.P. Pin, A. Cambria, I. Vranesic, P.J. Flor, F. Gasparini, and R. Kuhn The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a- carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors J. Biol. Chem. 275 2000 33750 33758
46. S. Parmentier-Batteur, J.A. O'Brien, S. Doran, S.J. Nguyen, R.B. Flick, J.M. Uslaner, H. Chen, E.N. Finger, T.M. Williams, M.A. Jacobson, and P.H. Hutson Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration Neuropharmacology 62 2012 1453 1460
47. K.G. Phillips, M.C. Cotel, A.P. McCarthy, D.M. Edgar, M. Tricklebank, M.J. O'Neill, M.W. Jones, and K.A. Wafford Differential effects of NMDA antagonists on high frequency and gamma EEG oscillations in a neurodevelopmental model of schizophrenia Neuropharmacology 62 2012 1359 1370
48. A. Pisani, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons Neuroscience 106 2001 579 587
49. A.L. Rodriguez, M.D. Grier, C.K. Jones, E.J. Herman, A.S. Kane, R.L. Smith, R. Williams, Y. Zhou, J.E. Marlo, E.L. Days, T.N. Blatt, S. Jadhav, U.N. Menon, P.N. Vinson, J.M. Rook, S.R. Stauffer, C.M. Niswender, C.W. Lindsley, C.D. Weaver, and P.J. Conn Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol. 78 2010 1105 1123
50. H. Rosenbrock, G. Kramer, S. Hobson, E. Koros, M. Grundl, M. Grauert, K.G. Reymann, and U.H. Schroder Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator Eur. J. Pharmacol. 639 2010 40 46
51. C. Schlumberger, M. Pietraszek, A. Gravius, and W. Danysz Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia Pharmacol. Biochem. Behav. 95 2010 23 30
52. C. Schlumberger, M. Pietraszek, A. Gravius, K.U. Klein, S. Greco, L. More, and W. Danysz Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity Eur. J. Pharmacol. 623 2009 73 83
53. D.D. Schoepp, D.E. Jane, and J.A. Monn Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38 1999 1431 1476
54. W.F. Seidel, M. Maze, W.C. Dement, and D.M. Edgar Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat J. Pharmacol. Exp. Ther. 275 1995 263 273
55. S. Sharma, J. Kedrowski, J.M. Rook, R.L. Smith, C.K. Jones, A.L. Rodriguez, P.J. Conn, and C.W. Lindsley Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines J. Med. Chem. 52 2009 4103 4106
56. N. Spear, R.A. Gadient, D.E. Wilkins, M. Do, J.S. Smith, K.L. Zeller, P. Schroeder, M. Zhang, J. Arora, and V. Chhajlani Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator Eur. J. Pharmacol. 659 2011 146 154
57. M.R. Stefani, and B. Moghaddam Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade Eur. J. Pharmacol. 639 2010 26 32
58. N.R. Swerdlow, M. Weber, Y. Qu, G.A. Light, and D.L. Braff Realistic expectations of prepulse inhibition in translational models for schizophrenia research Psychopharmacology (Berl.) 199 2008 331 388
59. J.M. Uslaner, S. Parmentier-Batteur, R.B. Flick, N.O. Surles, J.S. Lam, C.H. McNaughton, M.A. Jacobson, and P.H. Hutson Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus Neuropharmacology 57 2009 531 538
60. R.N. Van Gelder, D.M. Edgar, and W.C. Dement Real-time automated sleep scoring: validation of a microcomputer-based system for mice Sleep 14 1991 48 55
61. J.D. Vardigan, S.L. Huszar, C.H. McNaughton, P.H. Hutson, and J.M. Uslaner MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol. Biochem. Behav. 95 2010 223 229
62. Y. Zhang, A.L. Rodriguez, and P.J. Conn Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes J. Pharmacol. Exp. Ther. 315 2005 1212 1219